1. Introduction {#s0005}
===============

In addition to coronary and peripheral artery diseases, aortic diseases contribute to the wide spectrum of arterial diseases. These aortic diseases include aortic aneurysms and aortic dissection.[@b0005] The Global Burden Disease 2010 project demonstrated that the overall global death rate from aortic aneurysms and AD increased from 2.49 to 2.78 per 100,000 in habitants between 1990 and 2010, with higher rates for men.[@b0010]

A thoracic aortic aneurysm, is abnormal bulge in a weakened wall of the aorta in the chest area and can cause a variety of symptoms and often life-threatening complications. Due to the serious risks it presents, timely diagnosis and treatment of a thoracic aneurysms are critical. The standard surgical treatment for thoracic aortic aneurysms is open-chest aneurysm repair, but surgeons are now able to treat many thoracic and thoracoabdominal aneurysms with a minimally invasive procedure called an endovascular stent graft.[@b0015]

Aortic dissection is a potentially life-threatening condition that occurs when a tear is formed in the wall of the aorta. Stanford type B or DeBakey III aortic dissection originates in the descending thoracic aorta without retrograde extension into the ascending aorta. Type B aortic dissection may be classified as uncomplicated or complicated. Approximately 25% of patients presenting with type B aortic dissection are complicated at admission by malperfusion syndrome or hemodynamic instability, resulting in a high risk of early death if untreated.[@b0020]

An acute aortic dissection (\<2 weeks) is associated with high morbidity and mortality rates (highest mortality in the first 7 days).[@b0025] Because of the high mortality rates associated with surgery, stable patients with uncomplicated type B dissection usually receive non operative treatment. 70% of type B aortic dissections are uncomplicated and are medically treated only which carries a 50% 5-year mortality rate.[@b0030], [@b0035]

Patients with complicated type B aortic dissection secondary to aortic rupture, intractable pain, and/or end-organ ischemia because of aortic branch vessel involvement require intervention, but OSR is associated with high mortality rates. Such patients have increasingly been undergoing endovascular treatment, with encouraging results.[@b0040] The advent of endovascular repair of the thoracic aorta \[TEVAR\] has altered the management algorithm for pathologies that affect the aortic arch and descending thoracic aorta. In recent years, the number of thoracic endovascular procedures has risen.[@b0045]

The increased use of TEVAR has been driven by the early morbidity and mortality advantage reported when endovascular therapy is compared with open surgical treatment of the thoracic aorta.[@b0050] TEVAR is now considered the first-line therapy for isolated aneurysms of the descending thoracic aorta.[@b0055] TEVAR is recommended in treatment of complicated type B aortic dissection and should be considered in uncomplicated aortic dissection.[@b0060]

The aim of this study is to test the safety of using TEVAR in treating patients with aortic aneurysm and uncomplicated type B aortic dissection, in early intervention, and showed the outcome results through 12 months follow up.

2. Patients and methods {#s0010}
=======================

This study included 30 patients recruited from the patients with uncomplicated thoracic type B aortic dissection and descending aortic aneurysm who had expected life-span longer than 1 year and underwent endovascular aortic repair in National Heart Institute and Cairo University hospitals in the period between 2014 and 2016. Patients who had dissection involving the ascending aorta, severe valvular disease, CAD need surgical intervention, history of bleeding diathesis, sepsis or active endocarditis were excluded. The Ethical approval for research was obtained from the Research Ethics Committee, Faculty of Medicine, Cairo University.

All patients were subjected to full history and physical examination.12 lead ECG, chest X-ray, full echocardiographic evaluation were performed for all patients. All patients were subjected to CT scan including of thoracic, abdominal aorta and iliac-femoral axis. The following were calculated: Diameter of the aorta at different levels -- Size and morphology of the aneurysm and its relationship to the side branches -- Length (typically ≥ 20 mm) and diameter (typically ≤ 40 mm) of the healthy proximal and distal landing zones -- Site of the proximal entry tear of the dissection, its extent and the involvement of important aortic branches (e.g. left subclavian artery) -- Anatomy of the coronary arteries ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Example of AD.

A team of TEVAR includes two interventional cardiologists, a cardiac surgeon and an anesthesiologist. The procedure was done under general anesthesia and mechanical ventilation through trans-femoral approach. Common femoral artery was explored surgically with insertion of 6 French sheeth, an angled catheter and guidewire were used to access the abdominal aorta, and then advanced under fluoroscopic guidance into ascending aorta. It is important to keep this guidewire in place during the entire endovascular procedure. The anesthesiologist should be forewarned about these guidewires and watch for any arrhythmias they may cause. Deployment of Aortic stents differs from one company to another but all are self-expandable stents and we sometimes need post stenting dilatation in some cases, all the procedure was done under fluoroscopy and contrast injection for accurate positioning [Fig. 2](#f0010){ref-type="fig"}. In situations involving important aortic side branches (e.g. left subclavian artery), TEVAR was often preceded by limited surgical revascularization of these branches (the 'hybrid' approach).Fig. 2Define position of stent under fluoroscopy.

Clinical follow-up events included: death from all causes, Aorta related deaths, neurological deficits (stroke or TIAs), symptoms of chronic peripheral mal perfusion syndrome (claudication, abdominal pain) and 2ry endovascular or surgical re-intervention. Multi-slice CT was performed at average three and six months after intervention [Fig. 3](#f0015){ref-type="fig"}.Fig. 3Example of Post TEVAR.

2.1. Primary outcome measures {#s0015}
-----------------------------

The primary endpoints were technical success during implantation, 30-day all-cause mortality and surgical conversion. The technical success of TEVAR was defined as successful deployment of the stent graft with complete coverage of the primary entry tear and no signs of type I endoleak at the end of the procedure. Technical success during using hybrid technique included successful open visceral bypasses.

2.2. Secondary outcome measures {#s0020}
-------------------------------

The secondary endpoints were the procedure related complications and secondary procedures. Possible risk factors for graft related complications were also assessed. A complication was defined as any graft related complication: endoleak, endotension, migration, kinking or thrombosis of the stent graft.

3. Results {#s0025}
==========

This prospective observational study included 30 patients. Indications of the procedure in this study were listed in [Table 1](#t0005){ref-type="table"}.Table 1Indications for treatment.IndicationNo.*Aortic Dissection (N. 24)*Acute cases11Sub-acute cases7Chronic cases6Hybrid technique7Basic Endovascular technique17Survival21  *Aortic Aneurysm (N. 6)*Basic Endovascular technique6Survival6

**Group I**: included 24 who had uncomplicated Type B AD patients, 17 patients underwent pure TEVAR and 7 patients needed a Hybrid technique. The 24 uncomplicated Type B AD patients included 11 acute, 7 subacute and 6 chronic AD.

**Group II**: included 6 patients who had aortic aneurysm and underwent TEVAR.

There were male gender predominance (male 83.3% versus female 16.7%), with mean age (55.87 ± 9.61). Hypertensives were 27 patients, while diabetics were 5 patients. 18 patients had dyslipidemia and 8 patients had CAD. Smokers were 25 patients (83.3%) ([Table 2](#t0010){ref-type="table"} and [Fig. 4](#f0020){ref-type="fig"}).Table 2Baseline characteristics.CharacteristicsFrequencyNo.(%)Mean age (±SD)55.8 (32--76)\
(±9.6)*Gender*Male25(83.3)Female5(16.7)Hypertensives27(90)Diabetics5(16.7)Smokers25(83.3)Dyslipidemic patients18(60)CAD patients8(26.7)Fig. 4Distribution of the study cases according to history of hypertension, diabetes, dyslipidemia, CAD and smoking.

A postoperative stay in the intensive care unit (ICU) was needed for all patients. There was no significant difference in the ICU or overall hospital stay between cases (mean ICU stay 6.8 vs. 7.0 days, range 1--40 days, p value = 0.972).

**After twelve months of follow up, Complications reported were:**

Mortality rate was (10%). 3 patients out of the 7 patients in Group I who underwent hybrid technique died during hospital stay within the first 3 months -- one case had subacute AD and others had chronic AD. Cause of death was sepsis and acute renal failure. The 3 died patients had a more complicated proximal landing zone II requiring a carotid subclavian bypass to attain proximal seal. Non acute cases of AD had mainly weakness of the aortic wall and involvement of the great branches that need more caution to deal with. 2 cases developed endoleak type I -- one of them had subacute AD and the other case had chronic AD. Both cases improved during the first 3 months of follow up. Graft related complications as endotension, thrombosis, migration and kinking were not reported.

None of acute cases of aortic dissection nor thoracic aortic aneurysm died or developed endoleak after procedure ([Fig. 5](#f0025){ref-type="fig"}). In our series, the complications were more evident in the non acute cases of AD and this may indicate that the early use of TEVAR in acute cases of dissection is associated with better outcome. Complications that occurred in the 3 died patients were attributed to their chronic underlying pathology and the using of hybrid technique ([Fig. 6](#f0030){ref-type="fig"}, [Fig. 7](#f0035){ref-type="fig"}).Fig. 5Bar chart of the distribution according to complication after 12 months after TEVAR.Fig. 6Bar chart of the distribution of cases according to the mortality and pathology.Fig. 7Bar chart of mortality among the seven cases who underwent hybrid technique.

None of our patients developed stroke nor paraplegia and no TEVAR re-intervention for graft related complication as re-endografting, limb graft repair, embolization, femoro-femoral bypass, conversion to open repair was done during the twelve months of follow up in all sample cases of our study.

4. Discussion {#s0030}
=============

Regardless of the treatment method, aortic disease repair still have a considerable mortality and morbidity. Open surgical repair is applicable only to a selected group of patients and hybrid repair is still considered a major procedure. The use of endovascular treatment can minimize the surgical impact on patient with aortic disease, and help in treatment of more risky patients, with promising results.[@b0065]

Patients who underwent any aortic intervention (OSR or Endovascular repair) showed a significant survival advantage over those who were medically treated only as confirmed by Durham et al.[@b0070]

Cambria et al. studied the treatment advantages of TEVAR for thoracic aortic diseases when compared with literature -- based results of open surgical repair. They found that TEVAR is the preferred initial treatment for thoracic aortic catastrophes.[@b0075] TEVAR seems to have a more favorable outcome as regards aortic remodeling and the aortic specific survival rate when compared with OMT alone.[@b0080]

The result of the study of Miller et al. confirmed that TEVAR will not be widely used for the patient with uncomplicated type B aortic dissection until a prospective clinical trial shows a clear clinical advantages of TEVAR over medical management.[@b0085] So randomized controlled trials focusing on the prognostic factors of early and late complications in uncomplicated type B dissection are needed.

The results of endovascular repair in our study are promising as regards the use of TEVAR in patients with uncomplicated type B aortic dissection specially those with acute presentation. Technical success was high. The 30 day operative mortality rate was 10% which attributed to their chronic pathology and the using of hybrid technique.

In this prospective observational study, early use of TEVAR in acute cases with uncomplicated Type B AD and thoracic aortic aneurysm had no side effects and the success rate was 100%. Being sub-acute or chronic aortic disease are predictors of complications in Group I of patients, the earlier we used TEVAR the better outcome we get.

By comparing our study with the following studies, we found that most of these studies reached the same result of our study and the combination of early TEVAR with medical therapy seems to have a more favorable outcome e.g. Nienaber et al. who reported In INSTEAD XL Trial that TEVAR in addition to OMT is associated with improved 5-year aorta-specific survival and delayed disease progression.[@b0090] Also the result of Fattori et al. confirmed that TEVAR is associated with lower mortality over a 5-year period than medical therapy for TBAD.[@b0095] Shah et al. in a study compared between TEVAR and medical treatment outcomes of acute uncomplicated TBAD, he also found that using TEVAR to less complicated patients could only decrease TEVAR mortality rates.[@b0100]

Qin et al. also reported that TEVAR for uncomplicated type B aortic dissection in the acute setting was feasible with fewer aortic-related adverse events and a lower mortality rate compared with BMT.[@b0105] Chemelli-Steingruber et al. also reported in his study that TEVAR was a feasible treatment option in acute TBAD.[@b0110] Hughes in ADSORB trial, which evaluated TEVAR + BMT vs. BMT alone in patients with acute uncomplicated Type B AD, also reported zero mortality and neurological complication rates in both groups but aortic remodeling after one year was in favor of TEVAR.[@b0115] Kamman et al. also demonstrated from (ADSORB) trial database that uncomplicated Type B AD patients were at higher risk and should receive TEVAR.[@b0120]

5. Conclusion {#s0035}
=============

According to our study and despite the small number of patient population, early thoracic endovascular aortic repair in uncomplicated type B aortic dissections and descending thoracic aortic aneurysms with medical therapy is associated with better outcome.

6. Recommendation {#s0040}
=================

Although the ideal treatment for uncomplicated type B aortic dissection and aneurysm is still unclear, the combination of TEVAR with medical therapy seems to have a more favorable outcome as regard aortic remodeling and aorta-specific survival rate. Treating uncomplicated type B aortic dissection and aneurysm need further investigation and the outcome predicting factors of these patients may help in the identification of the best management. Until this issue is clarified, there is a need for more randomized clinical trials that will focus on the prognostic factors of early and late complications in uncomplicated aortic dissection and aneurysm and the timing of intervention.
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